MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2018 International Congress

    Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

    S. Isaacson (Boca Raton, FL, USA)

    Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…
  • 2018 International Congress

    Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

    M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

    Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…
  • 2018 International Congress

    Atypical Response to Apomorphine in a Patient with Multiple System Atrophy

    S. Ozben, F. Genc, F. Tuter Yilmaz, A. Erdal, N. Atis (Antalya, Turkey)

    Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…
  • 2017 International Congress

    Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

    H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

    Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…
  • 2017 International Congress

    ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

    L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

    Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…
  • 2017 International Congress

    Pharmaeconomic study of the treatment of advanced Parkinson’s disease.

    F. VIVANCOS-MATELLANO, A. SANZ, J.U. MIRÓ, J. CADAVID, A. RUÍZ, N. SOLER (Madrid, Spain)

    Objective: Conduct a comparative pharmacoeconomic analysis of the use of  subcutaneous apomorphine infusion pump (SAIP),   continuous levodopa/carbidopa duodenal infusión (LDI) and deep brain stimulation (DBS). Background:…
  • 2017 International Congress

    Alternative Apomorphine Challenge Test

    J.C. Martinez Castrillo, A. Alonso Canovas, C. Estevez Fraga, G. Sanchez Diez, I. Avilés Olmos, J. Lopez Sendon, P. Garcia Ruiz, L. Vela Desojo (Madrid, Spain)

    Objective: To propose a new apomorphine challenge test Background: In the standard apomorphine challenge test, the appropriate dose of apomorphine is established by incremental dosing…
  • 2017 International Congress

    The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

    R. Borgemeester, T. van Laar (Groningen, Netherlands)

    Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…
  • 2017 International Congress

    Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

    J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

    Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…
  • 2017 International Congress

    Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats

    K. Schwabe, J. Krauss, M. Alam (Hannover, Germany)

    Objective: The aim of our study was to investigate the effects of stimulation in the rat entopeduncular nucleus (EPN) on single neuronal activity of the…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley